viernes, 2 de diciembre de 2011

Genetic testing and screening of individuals at r... [Clin Genet. 2011] - PubMed - NCBI

Clin Genet. 2011 Nov 19. doi: 10.1111/j.1399-0004.2011.01816.x. [Epub ahead of print]

Genetic testing and screening of individuals at risk of NF2.

Evans DG, Raymond F, Barwell J, Halliday D.

Source

Department of Medical Genetics, University of Cambridge, Cambridge Institute for Medical Research, Addenbrookes Hospital, Cambridge CB2 0XY flr24@cam.ac.uk Department of Clinical Genetics, The Radcliffe Hopsitals NHS Trust, The Churchill, Old Rd, Headington, Oxford, OX3 7LJ dorothy.halliday@orh.nhs.uk Department of Clinical Genetics, Leicester Royal Infirmary, Leicester LE1 5WW jgb8@le.ac.uk .

Abstract

Background: Genetic testing and management of the at risk individual for neurofibromatosis type 2 (NF2) is complicated by the well documented risk of mosaicism that causes a milder later onset more asymmetrical disease course. Methods: Risks of NF2 were derived from genetic testing of over 1000 individuals through the Manchester NF2 testing service. Results and discussion: Individuals are at risk of NF2 or have 'potential' NF2 if they have features of the disease that fall short of diagnostic criteria or are the first degree relative of someone with NF2 or suspected NF2. The present protocol devised for the nationally commissioned NF2 service in England addresses the risks, genetic testing and screening protocol for individuals at risk of NF2. Screening with cranial MRI is advised until the risk of NF2 falls below a pragmatic threshold of 1%. Multiple case scenarios are shown to illustrate how to use the protocol.
© 2011 John Wiley & Sons A/S.